Published 20 hours ago • loading... • Updated 20 hours ago

Innovent Expands Phase III MarsLight-11 Trial to Non-Squamous NSCLC

Innovent Biologics is expanding its global Phase 3 MarsLight-11 trial to include patients with non-squamous non-small-cell lung cancer .
The expansion will create a new, independent substudy within the randomized, controlled MarsLight-11 trial, alongside the existing squamous NSCLC substudy.
Both substudies will compare IBI363 alone with docetaxel in patients whose advanced NSCLC progressed after platinum chemotherapy and anti-PD-1/PD-L1 treatment.

Insights by Ground AI

17 Articles

Missoulian

+14 Reposted by 14 other sources

Center

Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC

SAN FRANCISCO and SUZHOU, China, Sept. 27, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and ophthalmic…

1 day ago·Missoula, United States

Read Full Article

vir.com.vn

Innovent Biologics expands Phase 3 lung cancer trial globally

Biopharmaceutical manufacturer Innovent Biologics expanded its global Phase 3 MarsLight-11 clinical trial of candidate IBI363/TAK-928 to evaluate patients with immunotherapy-resistant non-squamous non-small cell lung cancer.

20 hours ago

Read Full Article

Verdict Hospital

Innovent expands Phase III MarsLight-11 trial to non-squamous NSCLC

Innovent Biologics has announced an expansion of its global Phase III MarsLight-11 trial evaluating IBI363, also known as TAK-928, to non-small cell lung cancer (NSCLC) patients.

20 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year